Skip to main content
padlock icon - secure page this page is secure

Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)

Buy Article:

$68.00 + tax (Refund Policy)

Protein tyrosine phosphatases (PTPs) are important in the regulation of diverse cellular functions including proliferation, migration and invasion; aberration of these cellular events is crucial for the development and progression of cancer. PTPs family comprises of two groups, classic PTPs and dual specificity phosphatases. The classic PTPs include both non-transmembrane PTPs and transmembrane receptor-like PTPs (RPTPs). RPTPs are composed of extracellular regions, transmembrane domains and intracellular phosphatase domains. The extracellular regions of RPTPs are similar to cell adhesion molecules and can interact homophilically and heterophilically. There are eight subgroups in the RPTPs separated according to the differences in their extracellular regions. PTPRK and PTPRM belong to the R2B subfamily of RPTPs and both perform homophilic interactions and regulate cell-cell aggregation and adhesion. Furthermore, both PTPRK and PTPRM can interact with the catenin/cadherin complex to regulate cell proliferation and migration. The current review discusses the present knowledge on RPTPs and their potential implication in the development and progression of cancer.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cancer; PTPRK; PTPRM and signal transductions; motility; proliferation; protein tyrosine phosphatases

Document Type: Research Article

Publication date: August 1, 2013

More about this publication?
  • In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.

    The aim of this journal is to publish timely in-depth reviews as well as original papers in the field of signal transduction therapy. Thematic issues will also be published to cover selected areas of signal transduction therapy. Coverage of the field will include genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases.

    Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more